{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:10:29Z","timestamp":1740107429527,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,10,29]],"date-time":"2015-10-29T00:00:00Z","timestamp":1446076800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,10,29]],"date-time":"2015-10-29T00:00:00Z","timestamp":1446076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA115811","P30 CA016672"],"award-info":[{"award-number":["CA115811","P30 CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s00280-015-2879-4","type":"journal-article","created":{"date-parts":[[2015,10,29]],"date-time":"2015-10-29T11:44:18Z","timestamp":1446119058000},"page":"1297-1307","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Analysis of redox and apoptotic effects of anthracyclines to delineate a cardioprotective strategy"],"prefix":"10.1007","volume":"76","author":[{"given":"Joy Marie","family":"Fulbright","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela E.","family":"Egas-Bejar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winston W.","family":"Huh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joya","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,29]]},"reference":[{"issue":"1","key":"2879_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.pharmthera.2011.07.006","volume":"133","author":"R Kizek","year":"2012","unstructured":"Kizek R, Adam V, Hrabeta J, Eckschlager T, Smutny S, Burda JV et al (2012) Anthracyclines and ellipticines as DNA-damaging anticancer drugs: recent advances. Pharmacol Therapeut 133(1):26\u201339","journal-title":"Pharmacol Therapeut"},{"issue":"5","key":"2879_CR2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1365-2141.2005.05759.x","volume":"131","author":"KA Wouters","year":"2005","unstructured":"Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE (2005) Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 131(5):561\u2013578","journal-title":"Br J Haematol"},{"issue":"22","key":"2879_CR3","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1001\/jama.2013.6296","volume":"309","author":"MM Hudson","year":"2013","unstructured":"Hudson MM, Ness KK, Gurney JG, Mulrooney DA, Chemaitilly W, Krull KR et al (2013) Clinical ascertainment of health outcomes among adults treated for childhood cancer. J Am Med Assoc 309(22):2371\u20132381","journal-title":"J Am Med Assoc"},{"issue":"13","key":"2879_CR4","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1200\/JCO.2011.34.8987","volume":"30","author":"JG Blanco","year":"2012","unstructured":"Blanco JG, Sun CL, Landier W, Chen L, Esparza-Duran D, Leisenring W et al (2012) Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes\u2013a report from the Children\u2019s Oncology Group. J Clin Oncol 30(13):1415\u20131421","journal-title":"J Clin Oncol"},{"issue":"26","key":"2879_CR5","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJM199506293322602","volume":"332","author":"SE Lipshultz","year":"1995","unstructured":"Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP et al (1995) Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. New Eng J Med 332(26):1738\u20131743","journal-title":"New Eng J Med"},{"issue":"12","key":"2879_CR6","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1056\/NEJMcibr1214975","volume":"368","author":"DB Sawyer","year":"2013","unstructured":"Sawyer DB (2013) Anthracyclines and heart failure. New Eng J Med 368(12):1154\u20131156","journal-title":"New Eng J Med"},{"issue":"11","key":"2879_CR7","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/nm.2919","volume":"18","author":"S Zhang","year":"2012","unstructured":"Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF et al (2012) Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 18(11):1639\u20131642","journal-title":"Nat Med"},{"issue":"5","key":"2879_CR8","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1080\/02841860601156165","volume":"46","author":"JM Appel","year":"2007","unstructured":"Appel JM, Nielsen D, Zerahn B, Jensen BV, Skagen K (2007) Anthracycline-induced chronic cardiotoxicity and heart failure. Acta Oncol 46(5):576\u2013580","journal-title":"Acta Oncol"},{"issue":"12","key":"2879_CR9","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nrclinonc.2013.195","volume":"10","author":"SE Lipshultz","year":"2013","unstructured":"Lipshultz SE, Cochran TR, Franco VI, Miller TL (2013) Treatment-related cardiotoxicity in survivors of childhood cancer. Nat Rev Clin Oncol 10(12):697\u2013710","journal-title":"Nat Rev Clin Oncol"},{"issue":"19","key":"2879_CR10","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1161\/01.CIR.0000093196.59829.DF","volume":"108","author":"D Lebrecht","year":"2003","unstructured":"Lebrecht D, Setzer B, Ketelsen UP, Haberstroh J, Walker UA (2003) Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation 108(19):2423\u20132429","journal-title":"Circulation"},{"issue":"1","key":"2879_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.7326\/0003-4819-125-1-199607010-00008","volume":"125","author":"K Shan","year":"1996","unstructured":"Shan K, Lincoff AM, Young JB (1996) Anthracycline-induced cardiotoxicity. Ann Intern Med 125(1):47\u201358","journal-title":"Ann Intern Med"},{"issue":"8","key":"2879_CR12","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1089\/ars.2012.4795","volume":"18","author":"M Sterba","year":"2013","unstructured":"Sterba M, Popelova O, Vavrova A, Jirkovsky E, Kovarikova P, Gersl V et al (2013) Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid Redox Signal 18(8):899\u2013929","journal-title":"Antioxid Redox Signal"},{"issue":"3","key":"2879_CR13","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.ijcard.2012.10.079","volume":"167","author":"M Lotrionte","year":"2013","unstructured":"Lotrionte M, Palazzoni G, Abbate A, De Marco E, Mezzaroma E, Di Persio S et al (2013) Cardiotoxicity of a non-pegylated liposomal doxorubicin-based regimen versus an epirubicin-based regimen for breast cancer: the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomized pilot study. Int J Cardiol 167(3):1055\u20131057","journal-title":"Int J Cardiol"},{"issue":"18","key":"2879_CR14","doi-asserted-by":"publisher","first-page":"8839","DOI":"10.1158\/0008-5472.CAN-07-1649","volume":"67","author":"YL Lyu","year":"2007","unstructured":"Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y et al (2007) Topoisomerase II beta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res 67(18):8839\u20138846","journal-title":"Cancer Res"},{"issue":"2","key":"2879_CR15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1172\/JCI72931","volume":"124","author":"Y Ichikawa","year":"2014","unstructured":"Ichikawa Y, Ghanefar M, Bayeva M, Wu R, Khechaduri A, Naga Prasad SV et al (2014) Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Investig 124(2):617\u2013630","journal-title":"J Clin Investig"},{"issue":"5","key":"2879_CR16","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.freeradbiomed.2011.05.018","volume":"51","author":"M Goodman","year":"2011","unstructured":"Goodman M, Bostick RM, Kucuk O, Jones DP (2011) Clinical trials of antioxidants as cancer prevention agents: past, present, and future. Free Radic Biol Med 51(5):1068\u20131084","journal-title":"Free Radic Biol Med"},{"issue":"3","key":"2879_CR17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1161\/01.RES.84.3.257","volume":"84","author":"DB Sawyer","year":"1999","unstructured":"Sawyer DB, Fukazawa R, Arstall MA, Kelly RA (1999) Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ Res 84(3):257\u2013265","journal-title":"Circ Res"},{"issue":"7","key":"2879_CR18","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S0006-2952(98)00307-4","volume":"57","author":"DA Gewirtz","year":"1999","unstructured":"Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57(7):727\u2013741","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"2879_CR19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/pr.56.2.6","volume":"56","author":"G Minotti","year":"2004","unstructured":"Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56(2):185\u2013229","journal-title":"Pharmacol Rev"},{"issue":"9","key":"2879_CR20","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1634\/theoncologist.12-9-1124","volume":"12","author":"G Mercuro","year":"2007","unstructured":"Mercuro G, Cadeddu C, Piras A, Dessi M, Madeddu C, Deidda M et al (2007) Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist 12(9):1124\u20131133","journal-title":"Oncologist"},{"issue":"6","key":"2879_CR21","doi-asserted-by":"crossref","first-page":"1298S","DOI":"10.1093\/ajcn\/54.6.1298s","volume":"54","author":"K Shimpo","year":"1991","unstructured":"Shimpo K, Nagatsu T, Yamada K, Sato T, Niimi H, Shamoto M et al (1991) Ascorbic acid and adriamycin toxicity. Am J Clin Nutr 54(6):1298S\u20131301S","journal-title":"Am J Clin Nutr"},{"issue":"8","key":"2879_CR22","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1517\/14656566.8.8.1039","volume":"8","author":"E Barry","year":"2007","unstructured":"Barry E, Alvarez JA, Scully RE, Miller TL, Lipshultz SE (2007) Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother 8(8):1039\u20131058","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"2879_CR23","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1002\/1097-0142(197212)30:6<1632::AID-CNCR2820300632>3.0.CO;2-S","volume":"30","author":"JA Gottlieb","year":"1972","unstructured":"Gottlieb JA, Baker LH, Quagliana JM, Luce JK, Whitecar JP Jr, Sinkovics JG et al (1972) Chemotherapy of sarcomas with a combination of adriamycin and dimethyl triazeno imidazole carboxamide. Cancer 30(6):1632\u20131638","journal-title":"Cancer"},{"issue":"1","key":"2879_CR24","first-page":"53","volume":"10","author":"C Myers","year":"1983","unstructured":"Myers C, Bonow R, Palmeri S, Jenkins J, Corden B, Locker G et al (1983) A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol 10(1):53\u201356","journal-title":"Semin Oncol"},{"issue":"3","key":"2879_CR25","doi-asserted-by":"publisher","first-page":"174","DOI":"10.4070\/kcj.2013.43.3.174","volume":"43","author":"SH Jo","year":"2013","unstructured":"Jo SH, Kim LS, Kim SA, Kim HS, Han SJ, Park WJ et al (2013) Evaluation of short-term use of N-acetylcysteine as a strategy for prevention of anthracycline-induced cardiomyopathy: EPOCH trial\u2014A Prospective Randomized Study. Korean Circ J 43(3):174\u2013181","journal-title":"Korean Circ J"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2879-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-015-2879-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2879-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2879-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T11:15:36Z","timestamp":1589627736000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-015-2879-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,29]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["2879"],"URL":"https:\/\/doi.org\/10.1007\/s00280-015-2879-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2015,10,29]]},"assertion":[{"value":"26 August 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"J.C. has received research support from Celgene and Nereus Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}